Disease relevance of Abreva

• Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex [1].
• In contrast, nonenveloped poliovirus was not susceptible to the inhibitory action of 1-docosanol [1].
• This article reports that 1-docosanol, a 22-carbon-long saturated alcohol, exerts a substantial inhibitory effect on replication of certain viruses (e.g., herpes simplex virus and respiratory syncytial virus) within primary target cells in vitro [1].
• Purpose: Tadenan (DEBAT, Paris, France) is a pharmaceutical agent used in the treatment of benign prostatic hyperplasia (BPH) [2].
• The alteration in the expression of myosin isoforms associated with obstruction-induced hypertrophy is reversed close to normal in the detrusor smooth muscle from Tadenan-treated obstructed rabbits [3].

High impact information on Abreva

• Tadenan, an extract of Pygeum africanum, is a therapeutic prescribed in Europe to relieve symptoms of obstructive bladder dysfunction secondary to benign prostatic hyperplasia [4].
• Tadenan daily resulted in reduced bladder hypertrophy, improved compliance, improved contractile responses to nearly normal levels of isolated bladder strips to all stimuli tested and reversal of obstruction induced structural damage to cellular and subcellular organelle membranes [4].
• RESULTS: Tadenan treatment of castrated/testosterone-replaced rats was performed in order to interfere with prostatic cell proliferation [5].
• CONCLUSIONS: The observed regulatory role of Tadenan on various prostatic components of the adenylyl cyclase system, together with previous findings on protein kinase C-mediated signal transduction, open a complex array of possibilities of direct actions of this phytotherapeutic agent in the prostate [5].
• The effect of a Pygeum africanum extract (Tadenan) (Pa), used in the treatment of micturition disorders associated with BPH, has been examined on the proliferation of rat prostatic stromal cells stimulated by different growth factors [6].

Chemical compound and disease context of Abreva

• BACKGROUND: There are 3 new topical treatments for herpes labialis that have either been approved by the US Food and Drug Administration (penciclovir cream [Denavir] and n-docosanol cream [Abreva]) or recently undergone extensive clinical evaluation (acyclovir cream) [7].

Biological context of Abreva

• IC50 values (ng/ml) were finasteride = 1; Permixon = 5,600; Talso = 7,000; Strogen Forte = 31,000; Prostagutt = 40,000; and Tadenan = 63,000 [8].
• In double-blind randomised trials Tadenan, a drug known to have growth factor antagonist activity, conferred significant improvement of urinary symptoms, maximum flow rate and residual volume, with no serious side-effects [9].
• A clinical and urodynamic study of tadenan in the treatment of benign prostatic hypertrophy [10].
• The reproductive effects of behenyl alcohol were investigated in a fertility and reproduction study, and an embryonic development study in rats and rabbits, respectively [11].
• Behenyl alcohol did not increase the number of revertants per plate compared to controls in the S. typhimurium assay, with or without metabolic activation [12].

Anatomical context of Abreva

• Our current hypothesis is that Tadenan may either prevent the activation of degradative enzymes (or generation of free radicals), or protect the intracellular membranes against the destructive effects of free radicals or degredative enzymes [13].
• Compound-related effects in dogs were limited to observations of pale feces, indicative of unabsorbed behenyl alcohol, at doses of 2000 mg/kg body weight/day [12].
• The studies reported here indicate that n-docosanol inhibits fusion of the HSV envelope with the plasma membrane [14].
• In addition, behenyl alcohol did not increase the frequency of bone marrow polychromatic erythrocyte (PCE) micronuclei in mice in vivo [12].
• The ultrastructure of the epithelium of bulbourethral glands after administration of the tadenan preparation [15].

Associations of Abreva with other chemical compounds

• Interactions between docosanol (n-docosanol, behenyl alcohol) and nucleoside or pyrophosphate analogs were investigated in vitro [16].
• Further studies are needed to compare treatment efficacy between topical penciclovir, docosanol, and ACV cream for RHL [17].
• OBJECTIVES: To evaluate the effect of Tadenan (TAD; Pygeum africanum extract) pretreatment on the micturition characteristics of conscious and anesthetized rats consequent to dihydrotestosterone (DHT) administration and to examine the influence of such treatment on the growth of the prostate [18].

Analytical, diagnostic and therapeutic context of Abreva

• The crossover study revealed that late treatment with n-docosanol 10% cream significantly reduced mean healing time compared to placebo [19].
• Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe [20].
• The current study was designed to determine whether pre-treating rabbits with a clinically relevant dose of Tadenan could prevent the bladder from developing the contractile dysfunctions that are induced by bilateral ischemia followed by reperfusion [21].

References